PHILADELPHIA Australia’s Pharmaxis has established a Philadelphia, Pa.-based subsidiary to serve the North American market.
The subsidiary will help the company commercialize two of its products; Aridol, a test for airway inflammation, and Bronchitol, a treatment for lung diseases.
Alan Robertson, Pharmaxis’ chief executive officer, said the company plans to start two U.S. Phase III trials of Bronchitol in the first quarter of 2008 and file a new drug application for Aridol with the FDA.
Pharmaxis is a specialist pharmaceutical company committed to the research, development and commercialization of human therapeutic products that address chronic respiratory and autoimmune diseases and the development of improved lung function tests.